Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413920 | 0.90 | KDM4E (0.43) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL4410148 | 0.90 | KDM4E (0.43) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL4409178 | 0.90 | KDM4E (0.43) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL4407509 | 0.90 | KDM4E (0.43) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL599823 | 0.87 | KDM4E (0.52) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL7261397 | 0.80 | MIF (0.37) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL20550833 | 0.79 | KDM4E (0.43) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL6761273 | 0.77 | KDM4E (0.41) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL1566968 | 0.77 | KDM4E (0.72) | KDM4ELMNACYP1A2CCR1CCR5 | |
| SCHEMBL30989132 | 0.77 | KDM4E (0.72) | KDM4ELMNACYP1A2CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107696-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INST NAT SANTE RECH MED (FR) | 2023-04-06 | — | — | US | disclosed |
| US-20210253591-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INST NAT SANTE RECH MED (FR) | 2021-08-19 | — | — | US | disclosed |
| US-11046704-B2 | Derivatives of porphyrins, their process of preparation and their use for treating viral infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-06-29 | — | — | US | disclosed |
| EP-3368023-B1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INST NAT SANTE RECH MED (FR) | 2021-03-17 | — | — | EP | disclosed |
| US-20200223858-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INST NAT SANTE RECH MED (FR) | 2020-07-16 | — | — | US | disclosed |
| US-10577375-B2 | Derivatives of porphyrins, their process of preparation and their use for treating viral infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20180319811-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-08 | — | — | US | disclosed |
| EP-3368023-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072319-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319811-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | MAVS, ZC3HAV1, ZC3HAV1L | KDM4E 2639/4885LMNA 1001/4885CYP1A2 3630/4885 |
| US-11046704-B2 | Derivatives of porphyrins, their process of preparation and their use for treating viral infections | MAVS, ZC3HAV1, ZC3HAV1L | KDM4E 2639/4885LMNA 1001/4885CYP1A2 3630/4885 |
| US-20200223858-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | MAVS, ZC3HAV1, ZC3HAV1L | KDM4E 2639/4885LMNA 1001/4885CYP1A2 3630/4885 |
| US-10577375-B2 | Derivatives of porphyrins, their process of preparation and their use for treating viral infections | MAVS, ZC3HAV1, ZC3HAV1L | KDM4E 2639/4885LMNA 1001/4885CYP1A2 3630/4885 |
| US-20210253591-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | MAVS, ZC3HAV1, ZC3HAV1L | KDM4E 2639/4885LMNA 1001/4885CYP1A2 3630/4885 |
| US-20230107696-A1 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | MAVS, POLRMT, ZC3HAV1 | KDM4E 2168/4885LMNA 1744/4885CYP1A2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.